Cargando…

No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D

INTRODUCTION: The balance between T(H)1, T(H)2, T(H)17, and regulatory T cells has been suggested to be disturbed in type 1 diabetes (T1D). We investigated this balance in peripheral blood mononuclear cells (PBMC) from children at risk of developing T1D and children with T1D. METHODS: We studied PBM...

Descripción completa

Detalles Bibliográficos
Autores principales: Walldén, Jenny, Honkanen, Jarno, Ilonen, Jorma, Ludvigsson, Johnny, Vaarala, Outi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218718/
https://www.ncbi.nlm.nih.gov/pubmed/22096343
_version_ 1782216714956570624
author Walldén, Jenny
Honkanen, Jarno
Ilonen, Jorma
Ludvigsson, Johnny
Vaarala, Outi
author_facet Walldén, Jenny
Honkanen, Jarno
Ilonen, Jorma
Ludvigsson, Johnny
Vaarala, Outi
author_sort Walldén, Jenny
collection PubMed
description INTRODUCTION: The balance between T(H)1, T(H)2, T(H)17, and regulatory T cells has been suggested to be disturbed in type 1 diabetes (T1D). We investigated this balance in peripheral blood mononuclear cells (PBMC) from children at risk of developing T1D and children with T1D. METHODS: We studied PBMC expression levels of markers related to T(H)1 (T-bet, IL-12Rβ(1), IL-12Rβ(2)), T(H)2 (GATA-3, IL-4Rα), T(H)17 (IL-17A), and regulatory T cells (Foxp3, ICOS, and CTLA-4) with real-time polymerase chain reaction from 17 children with T1D, 13 children with β-cell autoimmunity, 15 children with T1D risk-associated human leukocyte antigen (HLA) haplotypes, and 24 healthy, control children. RESULTS: We observed decreased expression levels of GATA-3 by PBMC of healthy children with autoantibodies compared to healthy, control children (p = 0.014) or children with HLA risk alleles (p = 0.032). Children with T1D demonstrated lower expression levels of T-bet, IL-12Rβ(1), and IL-4Rα both at diagnosis and 12 months later. CONCLUSION: We found no indication of aberrant activation of T(H)1, T(H)17, or Treg in peripheral blood from children with or without risk of T1D. The observed immunological differences between children at risk of and with T1D should be considered when immunopathogenesis of β-cell destruction is studied.
format Online
Article
Text
id pubmed-3218718
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32187182011-11-17 No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D Walldén, Jenny Honkanen, Jarno Ilonen, Jorma Ludvigsson, Johnny Vaarala, Outi J Inflamm Res Original Research INTRODUCTION: The balance between T(H)1, T(H)2, T(H)17, and regulatory T cells has been suggested to be disturbed in type 1 diabetes (T1D). We investigated this balance in peripheral blood mononuclear cells (PBMC) from children at risk of developing T1D and children with T1D. METHODS: We studied PBMC expression levels of markers related to T(H)1 (T-bet, IL-12Rβ(1), IL-12Rβ(2)), T(H)2 (GATA-3, IL-4Rα), T(H)17 (IL-17A), and regulatory T cells (Foxp3, ICOS, and CTLA-4) with real-time polymerase chain reaction from 17 children with T1D, 13 children with β-cell autoimmunity, 15 children with T1D risk-associated human leukocyte antigen (HLA) haplotypes, and 24 healthy, control children. RESULTS: We observed decreased expression levels of GATA-3 by PBMC of healthy children with autoantibodies compared to healthy, control children (p = 0.014) or children with HLA risk alleles (p = 0.032). Children with T1D demonstrated lower expression levels of T-bet, IL-12Rβ(1), and IL-4Rα both at diagnosis and 12 months later. CONCLUSION: We found no indication of aberrant activation of T(H)1, T(H)17, or Treg in peripheral blood from children with or without risk of T1D. The observed immunological differences between children at risk of and with T1D should be considered when immunopathogenesis of β-cell destruction is studied. Dove Medical Press 2008-09-01 /pmc/articles/PMC3218718/ /pubmed/22096343 Text en © 2008 Walldén et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Walldén, Jenny
Honkanen, Jarno
Ilonen, Jorma
Ludvigsson, Johnny
Vaarala, Outi
No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D
title No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D
title_full No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D
title_fullStr No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D
title_full_unstemmed No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D
title_short No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or T1D
title_sort no evidence for activation of t(h)1 or t(h)17 pathways in unstimulated peripheral blood mononuclear cells from children with β-cell autoimmunity or t1d
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218718/
https://www.ncbi.nlm.nih.gov/pubmed/22096343
work_keys_str_mv AT walldenjenny noevidenceforactivationofth1orth17pathwaysinunstimulatedperipheralbloodmononuclearcellsfromchildrenwithbcellautoimmunityort1d
AT honkanenjarno noevidenceforactivationofth1orth17pathwaysinunstimulatedperipheralbloodmononuclearcellsfromchildrenwithbcellautoimmunityort1d
AT ilonenjorma noevidenceforactivationofth1orth17pathwaysinunstimulatedperipheralbloodmononuclearcellsfromchildrenwithbcellautoimmunityort1d
AT ludvigssonjohnny noevidenceforactivationofth1orth17pathwaysinunstimulatedperipheralbloodmononuclearcellsfromchildrenwithbcellautoimmunityort1d
AT vaaralaouti noevidenceforactivationofth1orth17pathwaysinunstimulatedperipheralbloodmononuclearcellsfromchildrenwithbcellautoimmunityort1d